Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.
| Revenue (TTM) | $88.78M |
| Gross Profit (TTM) | $68.73M |
| EBITDA | $-38.41M |
| Operating Margin | -32.80% |
| Return on Equity | -90.30% |
| Return on Assets | -19.80% |
| Revenue/Share (TTM) | $2.10 |
| Book Value | $0.79 |
| Price-to-Book | 3.29 |
| Price-to-Sales (TTM) | 1.26 |
| EV/Revenue | 1.307 |
| EV/EBITDA | -5.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 6.20% |
| Shares Outstanding | $43.55M |
| Float | $37.81M |
| % Insiders | 4.58% |
| % Institutions | 61.78% |
Volatility is currently expanding
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2026 ended September 30, 2026.
REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, October 27, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LUNG and any ticker you trade — then tracks every position and per-strategy win rate.
